Stay updated with breaking news from Deepak Bhatt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An analysis of the ORAL Surveillance trial details the efficacy of tofacitinib relative to TNF inhibition based on history of ASCVD and baseline cardiovascular risk.
Each month, our editorial staff compiles a recap of the top news in endocrinology from the past month. Our April 2023 month in review features new FDA approvals, important phase 2 data, and in-depth clinician perspective.
Ahead of the sotagliflozin approval, Deepak Bhatt, MD, MPH, offers perspective into potential future research opportunities for the SGLT1/2 inhibitor and discusses the impact of a 3rd agent boasting SGLT2 inhibition receiving approval for heart failure.
Ahead of the May 27, 2023 PDUFA date, the HCPLive Cardiology editorial team spoke to a group of cardiologists to capture their perspective of the potential role of sotagliflozin.
An analysis of cost-effectiveness using data from SOLOIST-WHF provides insight into the varying cost-effectiveness of the agent as a treatment for worsening heart failure.